Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT) from its SEC filings: 2024 revenue $0, free cash flow -$142.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2024) | $0 |
| Net income | -$221.3 million |
| Free cash flow | -$142.2 million |
| Diluted EPS | $-0.31 |
| Cash | $419.4 million |
| Share count, 1 year | +7% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.